Inter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap?
Smani S, Jalfon M, Sundaresan V, Lokeshwar S, Nguyen J, Halstuch D, Khajir G, Cavallo J, Sprenkle P, Leapman M, Kim I. Inter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap? Urologic Oncology Seminars And Original Investigations 2024 PMID: 39438211, DOI: 10.1016/j.urolonc.2024.10.002.Peer-Reviewed Original ResearchClinically significant PCaPI-RADS scoreDetect clinically significant PCaReporting of prostate cancerInter-reader reliabilityProstate cancerPI-RADSDiagnostic accuracyReceiver operating characteristicInter-readerPresence of clinically significant PCaProstate Imaging Reporting & Data SystemDetect clinically significant diseasePI-RADS 3 lesionsTertiary academic care centerMRI fusion biopsyPI-RADS 3Significant PCaProstate cancer managementClinically significant diseaseInter-reader agreementSubgroup of lesionsAcademic care centerIntraclass correlationMpMRI interpretationMolecular Correlates of Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: A Systematic Review
Fazekas T, Pallauf M, Kufel J, Miszczyk M, Tsuboi I, Matsukawa A, Laukhtina E, Kardoust Parizi M, Mancon S, Cadenar A, Schulz R, Yanagisawa T, Baboudjian M, Szarvas T, Gandaglia G, Tilki D, Nyirády P, Rajwa P, Leapman M, Shariat S. Molecular Correlates of Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: A Systematic Review. European Urology Oncology 2024 PMID: 39414421, DOI: 10.1016/j.euo.2024.09.017.Peer-Reviewed Original ResearchProstate Imaging ReportingProstate cancerMagnetic resonance imagingMRI-invisible lesionsPI-RADSMRI visibilityImaging ReportingAssociated with oncologic outcomesBiologically aggressive prostate cancerHighest Prostate Imaging ReportingMultiparametric magnetic resonance imagingProstate magnetic resonance imagingPI-RADS 4PI-RADS scoreResonance imagingData System scoreAggressive prostate cancerStage prostate cancerMolecular correlatesClinically aggressive cancerPrognostic gene panelsSystematic biopsyAssociated with featuresOncological outcomesSystemic biopsyMagnetic Resonance Imaging in Prostate Cancer Screening
Fazekas T, Shim S, Basile G, Baboudjian M, Kói T, Przydacz M, Abufaraj M, Ploussard G, Kasivisvanathan V, Rivas J, Gandaglia G, Szarvas T, Schoots I, van den Bergh R, Leapman M, Nyirády P, Shariat S, Rajwa P. Magnetic Resonance Imaging in Prostate Cancer Screening. JAMA Oncology 2024, 10: 745-754. PMID: 38576242, PMCID: PMC10998247, DOI: 10.1001/jamaoncol.2024.0734.Peer-Reviewed Original ResearchClinically significant PCaDetection of clinically significant PcaInternational Society of Urological PathologyClinically significant PCa detectionProstate magnetic resonance imagingMagnetic resonance imagingInsignificant PCaProstate cancerProstate cancer screeningBiopsy indicationClinically significant PCa detection rateProstate-specific antigen (PSA)-based screeningMagnetic resonance imaging pathwayOdds ratioPCa detection rateSignificant PCaPI-RADS scorePSA-based screeningResonance imagingScreening pathwayTime of magnetic resonance imagingPositive predictive valuePooled odds ratioProspective cohort studyRandomized clinical trials